All In Biotech

Drug Trial Radar · NCT07794774

A Study to Learn About Safety and Effects of Once-monthly Treatment With Berobenatide in Adults With Obesity Disease in Japan (VESPER-JM)

A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF ONCE-MONTHLY BEROBENATIDE IN ADULTS WITH OBESITY DISEASE IN JAPAN (VESPER-JM)

Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 197 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

197

Planned (sponsor's estimate)

Start

Sep 29, 2026

Primary completion

Feb 21, 2029

Study completion Feb 21, 2029

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Aug 31, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this clinical study is to learn about safety and effects of berobenatide (PF-08653944) in adults with obesity disease, a condition in which a person has too much body fat, which can harm their health and increase the risk of other medical problems. Some participants in this study may also have type 2 diabetes, a condition in which the body does not use insulin properly, causing blood sugar levels to become too high. This study is seeking participants in Japan who: * Have obesity disease. * May have type 2 diabetes. * Meet the study-specific age, weight, and health requirements. About 197 adults will take part in this study. Participants will be randomly assigned to receive either berobenatide or a placebo. A placebo looks like the study medicine but does not contain any active medicine. Berobenatide or placebo will be given as an injection under the skin of the abdomen (belly area). The study will compare the experiences of people receiving berobenatide with those receiving placebo to determine whether berobenatide can help people lose weight. The study will also assess the safety of berobenatide and its effects on body weight and other health measures. People will take part in this study for about 21 months. During this time, they will have about 16 study visits at the site. They will also have 2 study visits over the phone.

Conditions

  • Obesity

Interventions

  • BerobenatideDrug

    Subcutaneous Injection

  • PlaceboOther

    Subcutaneous Injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent change from baseline in body weightTime frame: Baseline, Week 72

Locations

36 sites in 1 country. Site status is shown where the registry gives one.

  • Nihonbashi Sakura Clinic

    Tokyo, Japan · Recruiting

  • Tokuyama Clinic

    Mihama-ku, Chiba, Japan · Recruiting

  • Mikannohana Clinic, Diabetes, Endocrinology and Metabolism

    Matsuyama, Ehime, Japan · Recruiting

  • Matsuyama Shimin Hospital

    Matsuyama, Ehime, Japan · Recruiting

  • Tenjin Sogo Clinic

    Fukuoka, Fukuoka, Japan · Recruiting

  • Medical Corporation BOOCS BOOCS CLINIC FUKUOKA

    Fukuoka, Fukuoka, Japan · Recruiting

  • Fukuoka Diagnostic Imaging Clinic Me-Well

    Fukuoka, Fukuoka, Japan · Recruiting

  • Oishi Clinic

    Kasuya-gun, Fukuoka, Japan · Recruiting

  • Manda Memorial Hospital

    Sapporo, Hokkaido, Japan · Recruiting

  • Yamasaki Family Clinic

    Amagasaki, Hyōgo, Japan · Recruiting

  • Minami Akatsuka Clinic

    Mito, Ibaraki, Japan · Not yet recruiting

  • Mito Saiseikai General Hospital

    Mito, Ibaraki, Japan · Not yet recruiting

  • Nishiyamado Keiwa Hospital

    Naka, Ibaraki, Japan · Recruiting

  • Olive Takamatsu Medical Clinic

    Takamatsu, Kagawa-ken, Japan · Recruiting

  • Medical Corporation Hitomikai Motomachi Takatsuka Naika Clinic

    Yokohama, Kanagawa, Japan · Recruiting

  • Yokoi Clinic

    Minoh, Osaka, Japan · Recruiting

  • Kanemura Clinic

    Osaka-shi Ikuno-ku, Osaka, Japan · Recruiting

  • Medical Corporation Heishinkai OCROM Clinic

    Suita, Osaka, Japan · Recruiting

  • MI Clinic, Medical Corporation Jinsenkai

    Toyonaka-shi, Osaka, Japan · Recruiting

  • Soka Sugiura Internal medicine Clinic

    Soka-shi, Saitama, Japan · Recruiting

  • Saiyu Soka Hospital

    Soka-shi, Saitama, Japan · Recruiting

  • Doujin Memorial Foundation Meiwa Hospital

    Chiyoda-ku, Tokyo, Japan · Recruiting

  • Aic Yaesu Clinic

    Chuo-ku, Tokyo, Japan · Recruiting

  • Tokyo Center Clinic

    Chuo-ku, Tokyo, Japan · Recruiting

  • Tokyo-Eki Center-building Clinic

    Chuo-ku, Tokyo, Japan · Recruiting

  • Fukuwa Clinic

    Chuo-ku, Tokyo, Japan · Recruiting

  • Tokyo Asbo Clinic

    Chuo-ku, Tokyo, Japan · Recruiting

  • Keikokai Medical Corporation P-one Clinic

    Hachiōji, Tokyo, Japan · Recruiting

  • Medical Corp. Seikoukai New Medical Research System Clinic

    Hachioji-shi, Tokyo, Japan · Recruiting

  • Hachioji Clinic Shincho

    Hachioji-shi, Tokyo, Japan · Recruiting

  • Patient First Clinic Ginza-Shimbashi

    Minato-ku, Tokyo, Japan · Recruiting

  • Shimamura Memorial Hospital

    Nerima-ku, Tokyo, Japan · Recruiting

  • Medical Corporation Heishinkai ToCROM Clinic

    Shinjuku-ku, Tokyo, Japan · Recruiting

  • Seeds Clinic Shinjuku-Sanchome, Eijinkai Medical Corporation

    Shinjuku-ku, Tokyo, Japan · Recruiting

  • Higashi-Shinjuku Clinic, Keikokai Medical Corp.

    Shinjuku-ku, Tokyo, Japan · Recruiting

  • Ikebukuro Metropolitan Clinic

    Toshima-ku, Tokyo, Japan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.